Breaking News
Sort by:
Top Post
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo® (cemiplimab) Combination in NSCLC
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced the expansion of its strategic collaboration […]
Miiskin Opens Skin Tracking Platform to Dermatology Research
Digital skin health platform Miiskin has opened its technology to give academic researchers free access – supporting […]
NEC OncoImmunity Acquires VAXIMM's Neoantigen Vaccine Development Assets
NEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and VAXIMM AG, a Swiss/German biotech […]
HCS Pharma Expects 90% Success Rate on Cancer Drugs Tests Due to Recreation of Organs In-vitro with BIOMIMESYS® Technology
Cancer is the second cause of death in the world and has been steadily increasing […]
Cannabotech's "Integrative-Colon" Products Eliminated Over 90% of Colon Cancer Cells in a Cell Model Experiment
Cannabotech, a biomedical company developing oncological products based on cannabis and mushroom extracts, reports cell […]
Targovax ASA and Agenus Announce Collaboration on Mutant KRAS Cancer Vaccine Adjuvanted with QS-21 STIMULON™
Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, […]
Immunovia Further Strengthens IP Portfolio for its IMMray ™ PanCan-d Signature
Immunovia AB (publ) announced today that the United States Patent and Trademark Office (USPTO) has […]
AnchorDx Appoints Dr. Marina Bibikova as Chief Scientific Officer
AnchorDx, a world-leading developer of cancer screening and early detection solutions, is delighted to announce that Dr. […]
Tollys and Gustave Roussy Enter into New Research Agreement
Tollys, a biopharmaceutical company developing TL-532, the first anti-cancer immunotherapy based on a synthetic toll-like […]
Hundreds of Patients to Benefit From Revolutionary Lung Cancer Drug On The NHS
A revolutionary targeted drug for lung cancer will be made available to anyone who is […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more